Bacteremia due to <i>Rothia mucilaginosa</i> after chemotherapy for myeloid malignancies

DOI Web Site PubMed
  • KOHASHI Sumiko
    Division of Hematology, Department of Medicine, Keio University School of Medicine
  • MORI Takehiko
    Division of Hematology, Department of Medicine, Keio University School of Medicine Center for Infectious Disease and Infection Control, Keio University Hospital
  • KODA Yuya
    Division of Hematology, Department of Medicine, Keio University School of Medicine
  • KIKUCHI Taku
    Division of Hematology, Department of Medicine, Keio University School of Medicine
  • KATO Jun
    Division of Hematology, Department of Medicine, Keio University School of Medicine
  • SHIMIZU Takayuki
    Division of Hematology, Department of Medicine, Keio University School of Medicine
  • SUGITA Kayoko
    Center for Infectious Disease and Infection Control, Keio University Hospital
  • HASEGAWA Naoki
    Center for Infectious Disease and Infection Control, Keio University Hospital
  • MURATA Mitsuru
    Department of Laboratory Medicine, Keio University School of Medicine
  • OKAMOTO Shinichiro
    Division of Hematology, Department of Medicine, Keio University School of Medicine

Bibliographic Information

Other Title
  • 骨髄系腫瘍に対する化学療法後の<i>Rothia mucilaginosa</i>による菌血症
  • 症例報告 骨髄系腫瘍に対する化学療法後のRothia mucilaginosaによる菌血症
  • ショウレイ ホウコク コツズイケイ シュヨウ ニ タイスル カガク リョウホウ ゴ ノ Rothia mucilaginosa ニ ヨル キンケッショウ

Search this article

Abstract

The number of reported cases of bacteremia due to Rothia mucilaginosa (R. mucilaginosa), a component of the normal flora of human gastrointestinal tract mucosa, is limited. We encountered three cases of bacteremia due to R. mucilaginosa during neutropenia after chemotherapy for myeloid malignancies. Although all three patients were successfully treated with antimicrobial agents, one patient developed disseminated lesions in the lungs and soft tissue. The portal of R. mucilaginosa bacteremia is reportedly mucositis or dental disorders; however, no such complications were identified in our patients. Even in the absence of a preexisting portal, R. mucilaginosa should be recognized as a potential causative pathogen of bacteremia during neutropenic periods. Accumulations of cases and isolates are required to further elucidate the risk factors for developing R. mucilaginosa bacteremia, its clinical course, and the optimal antimicrobial treatment.

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 56 (6), 687-691, 2015

    The Japanese Society of Hematology

Keywords

Details 詳細情報について

Report a problem

Back to top